All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Innovate UK
Deal Size: $475.0 million Upfront Cash: Undisclosed
Deal Type: Funding March 08, 2021
Details:
Pathios Therapeutics will team up with researchers at The University of Oxford to accelerate cancer immunotherapies targeting GPR65 on immunosuppressive macrophages.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cell therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Kite Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 06, 2021
Details:
Oxford BioTherapeutics will validate five novel oncology drug targets, previously identified using OBT’s OGAP® discovery platform, and generate antibodies against these targets.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Humabody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration December 10, 2020
Details:
The expansion will enable Takeda to access a range of Crescendo’s half-life extension Humabodies for use with its two Humabody programmes, licensed in November 2018 and July 2019.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LentiVector based gene therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Oxford Biomedica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 09, 2020
Details:
PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER®, to identify therapeutic candidates for Oxford Biomedica’s LentiVector® gene therapy delivery system.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): APN431
Therapeutic Area: Oncology Product Name: APN431
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Apeiron Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 09, 2020
Details:
Domainex will provide its expertise in medicinal and computational chemistry, screening, structural biology and ADME/PK to advance APEIRON’s promising Cbl-b targeting compound series APN431 towards pre-clinical development.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Jazz Pharmaceuticals
Deal Size: $420.0 million Upfront Cash: $10.0 million
Deal Type: Collaboration September 09, 2020
Details:
Under the terms of the collaboration agreement, Redx will be responsible for research and preclinical development activities up to Investigational New Drug (IND) submission.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): C0021158
Therapeutic Area: Oncology Product Name: C0021158
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2020
Details:
ARG2 targets and destroys L-arginine, an amino acid critical for immune cells to fight diseases such as cancer, as well as infections.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
